Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
By Junko Matsuzaki, S. Gnjatic, P. Mhawech-Fauceglia, A. Beck, Austin Miller, T. Tsuji, C. Eppolito, F. Qian, S. Lele, P. Shrikant and 2 more. Proceedings of the National Academy of Sciences of the United States of America, 2010
830 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/ca272f830e93c598dcbaffe86391a7d9944595e3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity (2012, positive): “Recent studies extended this concept to cancer; PD-1/LAG-3 co-expression was documented on tumor antigen-specific CD8+ T cells in women with ovarian cancer, and dual (but not single) blockade was shown to restore CD8+ T cell function in vitro [36].”
- T Cell Dysfunction in Cancer (2018, background): “Co-expression of PD-1 and Lag-3 has been observed on both virus- and tumor antigen-specific T cells (Grosso et al., 2009; Matsuzaki et al., 2010; Wherry et al., 2007).”
- Overcoming T cell exhaustion in infection and cancer (2015, background): “Recent clinical trials have shown that blocking the PD-1:PD-L1 pathway enhances immunity in several cancer types including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and others, leading to objective responses in a number of patients [16, 21–23, 25–32].”
- Immune checkpoint blockade: a common denominator approach to cancer therapy (2015, background): “A role for dual blockade of LAG-3 and PD-1 in tumor immunity is suggested by studies in which most tumors implanted in PD-1/LAG-3 double-knockout mice were rejected, whereas PD-1 single-knockout mice showed delayed tumor growth.”
- PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “Thus, the combinations of PD pathway with Tim-3, LAG3, and TIGIT blockade have been proposed and tested in clinical trials (NCT01968109 and NCT02460224).”
- CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. (2019, background): “Indeed, tumor-specific CD8 T cells display hallmarks of T cell exhaustion and dysfunction in mouse models (24, 25) and human cancers including, but not limited to, melanoma (26–30), chronic myeloid leukemia (24), ovarian cancer (31), non–small cell carcinoma (32, 33), Hodgkin lymphoma (34), and chro”